Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

J. Kuter, David; Ghanima, Waleed; Cooper, Nichola; A. Liebman, Howard; Zhang, Lei; Hu, Yu; Miyakawa, Yoshitaka; Homenda, Wojciech; Elena Morales Galindo, Luisa; Lisa Basquiera, Ana; Wen Tan, Chuen; Saydam, Guray; Luise Hütter-Krönke, Marie; Chai-Adisaksopha, Chatree; Gómez-Almaguer, David; Tran, Huy; Shin, Ho-Jin; Dantas da Cunha Junior, Ademar; Lazar, Zsolt; Pascual Izquierdo, Cristina; Kirgner, Ilya; Lucchini, Elisa; Kuzmina, Ganna; Fillitz, Michael; Audia, Sylvain; Taparia, Minakshi; Cordoba, Matias; Diab, Remco; Yao, Mengjie; Gouia, Imene; Lee, Michelle; Daak, Ahmed

doi:10.1182/blood.2024027336

Public

Safety and efficacy of rilzabrutinib vs placebo in adults with immune thrombocytopenia: the phase 3 LUNA3 study

Shared by NobleBlocks on Jun 12, 2025 • 12:00 AM UTC

Authors:

David J. Kuter

Waleed Ghanima

Nichola Cooper

Abstract

Abstract Rilzabrutinib is a covalent, reversible Bruton tyrosine kinase inhibitor targeting multiple immune thrombocytopenia (ITP)-related mechanisms. The phase 3 LUNA3 study in previously treated adults with persistent/chronic ITP evaluated oral rilzabrutinib 400 mg twice daily (n = 133) vs placebo...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!